MYGN

- Interested in Quest Diagnostics Incorporated? Here are five stocks we like better. - Quest Diagnostics reported strong Q3 results, with revenue up 10% to $3.1 billion and adjusted EPS rising 15.4% to $3.00. Growth was supported by higher testing volumes, demand across physician, hospital and consumer channels, and productivity gains from automation and AI. - The company raised and narrowed its 2026 outlook, forecasting revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35. Consumer-health revenue is expected to grow more than 30%, helped by a planned Apple Health testing offering priced at $119. - Management flagged potential headwinds from 2027 PAMA reimbursement changes, estimating an impact of about 1% of total revenue, and disclosed unauthorized access to a client test-ordering system; the incident has not materially disrupted operations, though the investigation is ongoing. - Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests Quest Diagnostics (NYSE:DGX) reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and narrowed its full-year revenue and earnings outlook. Chairman, Chief Executive Officer and President Jim Davis said the company's organic growth reflected expanding clinical needs among an aging population and increased consumer interest in preventive health and wellness. "We grew revenues 10% and adjusted earnings per share over 15% in the quarter," Davis said. → Aurora Rejects Curaleaf's Higher Bid, But the Takeover Fight Isn't Over - LifeMD Shares Come Back to Life on GLP-1 Business Growth Chief Financial Officer Sam Samad said consolidated revenue totaled $3.1 billion, up 10% from the prior-year quarter. Diagnostic information services revenue increased 10.2%, or 10.1% organically. Total requisition volume rose 14.5%, while organic volume increased 14.4%. Quest's relationships with Corewell Health and Fresenius Medical Care accounted for 9.5% of quarterly volume. Excluding those relationships, volume increased 5%. → Could Quantinuum's Breakthrough Make Its Sell-Off a Bargain? - Exact Sciences Serves Investors Exactly What They Wished For Revenue per requisition declined 4.2% on a reported basis because of the business mix associated with Corewell and Fresenius. Excluding those relationships, revenue per requisition increased 1.7%, driven mainly by a greater number of tests per requisition. Unit-price reimbursement was generally flat, Samad said. - Reported operating income was $479 million, or 15.5% of revenue, compared with $386 million, or 13.7% of revenue, a year earlier. - Adjusted operating income was $517 million, or 16.7% of revenue, up from $458 million, or 16.3% of revenue, in the prior-year period. - Reported diluted EPS was $2.78, compared with $2.16 a year earlier. - Adjusted diluted EPS rose 15.4% to $3.00 from $2.60. - Year-to-date cash from operations was $1.49 billion, compared with $1.42 billion in the prior year. The 40-basis-point improvement in adjusted operating margin was driven by organic revenue growth, partly offset by wage increases and the mix effect from the Corewell and Fresenius businesses, according to Samad. → IonQ's Bold Expansion Could Leave Shareholders Paying the Price Davis said the physician channel posted high-single-digit revenue growth, while the hospital channel grew revenue by double digits, aided by Co-Lab Solutions with Corewell Health in Michigan. Hospital reference-testing revenue grew in the mid-single digits. The company also finalized a definitive agreement to acquire select outreach assets from a longtime Co-Lab customer, described as a leading health system in the Northeastern U.S. Quest expects the transaction to close later this year. Consumer health remains a faster-growing channel, with Quest expecting growth exceeding 30% for the full year. The company announced that iPhone and iPad users will be able to order laboratory tests through the Apple Health app. The offering, expected to fully launch later this year, will allow users to purchase, schedule and receive results for more than 50 biomarkers, including ApoB and Lp(a), through the app. The panel will also include biometric measurements such as blood pressure and weight when blood is drawn at one of Quest's 2,000 patient service centers. Davis said the service will be priced at $119. Samad said consumer health margins are accretive to Quest's overall operating margins because of dense test requisitions and the absence of denials and patient concessions. Quest said key advanced-diagnostics tests grew revenue by double digits in areas including cardiometabolic testing, hormone testing and Alzheimer's disease testing. Davis said the company plans to add the FDA-cleared Roche p-tau217 test to its portfolio and has launched an AD-Detect panel including APOE, amyloid beta and p-tau217 biomarkers. In women's health, Quest formed an industry collaboration with Waters Corporation to provide access to Onclarity self-collection kits through clinical, health-plan and consumer-health channels. Quest expects to introduce the at-home option next year. The company remains on track to achieve 3% in annual cost savings and productivity improvements through its Invigorate program. During the quarter, Quest expanded automated specimen aliquoting to three drug-monitoring laboratories, bringing the total number of labs using the technology to 10. It also began using AI at its Clifton, New Jersey, laboratory to scan dialysis water for microbes and impurities. Quest's Project Nova initiative, which is intended to enhance provider and patient experiences, moved from the design phase to the solutions-build phase. The company expects to begin deploying Epic Solutions in its first laboratory in fall 2027. Project Nova is expected to reduce 2026 EPS by $0.25, with about 70% of that expense incurred in the second half of the year. Quest now expects full-year 2026 revenue of $12.065 billion to $12.105 billion, representing growth of 9.3% to 9.7%. The company projected reported EPS of $10.21 to $10.31 and adjusted EPS of $11.25 to $11.35. It expects approximately $1.9 billion in operating cash flow and about $550 million in capital expenditures. Management also addressed the preliminary 2027 rate-setting process under the Protecting Access to Medicare Act, or PAMA. Samad said Quest estimates the 2027 PAMA effect at about 1% of total company revenue, with the cumulative effect for 2027 through 2029 expected to be less than 1.3% of revenue. Davis said the company intends to offset a portion of the potential impact through efficiencies, while preserving investments that support growth, frontline staffing and laboratory operations. Quest and the American Clinical Laboratory Association continue to support the RESULTS Act, legislation intended to reform the PAMA data-collection process. Separately, Samad said Quest learned of unauthorized access to a test-ordering system used by certain clients that do not use an electronic medical record system. He said the incident had not materially disrupted operations or the company's ability to serve physicians and patients, while noting that the investigation remains in its early stages. Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services. Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call" was originally published by MarketBeat. View MarketBeat's top stocks for October 2026.

A month has gone by since the last earnings report for Adma Biologics (ADMA). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Adma Biologics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness ADMA Biologics reported second-quarter 2026 earnings of 16 cents per share, which matched the Zacks Consensus Estimate and rose from 14 cents in the year-ago quarter. Revenues grew 2.0% year over year to $124.4 million but missed the Zacks Consensus Estimate of $126.0 million. ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus). Strong Asceniv growth and margin expansion were partly offset by a sharp year-over-year decline in Bivigam sales. ADMA’s Asceniv Sales Maintain Strong Momentum Asceniv revenues increased 23.5% year over year to $102.9 million. The product accounted for most of ADMA’s quarterly revenues and remained the company’s principal growth driver amid competitive pressure across the broader U.S. immune globulin market. Management stated that Asceniv utilization strengthened progressively during the quarter. June produced the strongest sequential month-over-month utilization growth since the first half of 2024, supported by new patient starts, broader prescriber engagement and higher patient utilization. ADMA Biologics Faces Continued Bivigam Pressure Bivigam revenues plunged 48.5% year over year to $19.4 million. Increased supply, aggressive discounting and competitive pricing continued to pressure the standard immune globulin market. However, Bivigam revenues improved sequentially. Management said demand stabilized during the second quarter and expects the product’s current run rate to remain sustainable, though the company is not incorporating a meaningful recovery into its guidance. ADMA’s Product Mix Drives Margin Expansion Gross profit increased to $86.3 million from $67.2 million in the prior-year period. Gross margin expanded to 69% from 55%, reflecting a greater contribution from the higher-margin Asceniv product and benefits from the yield-enhanced manufacturing process approved in 2025. The shift in revenue mix supported substantial earnings leverage despite modest top-line growth. ADMA Biologics Steps Up Pipeline Investment Research and development expenses climbed to $6.0 million from $1.0 million a year earlier, primarily due to investments in the SG-001 development program. Management expects quarterly R&D spending to remain near the second-quarter level, with another increase anticipated in the fourth quarter. Selling, general and administrative expenses rose to $26.7 million from $22.2 million recorded a year earlier, mainly due to higher employee-related expenses, increased software maintenance costs, greater legal and consulting fees, and investments in strategic growth initiatives. ADMA Biologics Maintains Its 2026 Outlook ADMA reiterated its 2026 revenue guidance of $530-$560 million. The company continues to expect adjusted net income in the band of $170-$200 million and adjusted EBITDA in the $265-$300 million range. The outlook assumes persistent competitive dynamics and pricing pressure in the standard immune globulin market. Asceniv is expected to remain the main driver of revenue growth, profitability and cash generation, with management forecasting upper-20% to low-30% revenue growth for the product in 2026. ADMA’s Cash Flow Supports Share Repurchases ADMA ended the quarter with $136.0 million in cash and cash equivalents. The company repurchased approximately 7.1 million shares during the quarter. Year-to-date repurchases totaled about 13.8 million shares, representing 5.3% of outstanding common stock as of June 30, 2026. ADMA remains on track to complete at least $200 million of share repurchases during 2026. ADMA Biologics Advances SG-001 ADMA continued progressing SG-001, its hyperimmune globulin program targeting S. pneumoniae. ADMA expects to submit a pre-investigational new drug meeting package to the FDA by the end of 2026 and believes the candidate could address a $300-$500 million annual revenue opportunity if approved. Estimates review followed a downward path over the past two months. At this time, Adma Biologics has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of B on the value side, putting it in the second quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Adma Biologics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Adma Biologics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Myriad Genetics (MYGN), has gained 1.6% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Myriad reported revenues of $190.7 million in the last reported quarter, representing a year-over-year change of -10.5%. EPS of -$0.25 for the same period compares with $0.05 a year ago. For the current quarter, Myriad is expected to post a loss of $0.16 per share, indicating a change of 0% from the year-ago quarter. The Zacks Consensus Estimate has changed -118.2% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #5 (Strong Sell) for Myriad. Also, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

A month has gone by since the last earnings report for Harmony Biosciences Holdings, Inc. (HRMY). Shares have added about 12.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Harmony Biosciences due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Harmony Biosciences Holdings, Inc. before we dive into how investors and analysts have reacted as of late. HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales Harmony Biosciences Holdings reported second-quarter 2026 earnings of $1.28 per share, up from 68 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate of 97 cents. Quarterly revenues rose 30% year over year to $261.28 million and surpassed the Zacks Consensus Estimate of $253 million. Growth was driven by sustained demand for lead drug, Wakix (pitolisant), with the estimated average patient count increasing by 450 sequentially to 8,950. HRMY Q2 Cost Analysis Cost of products sold represented 24.2% of product revenues compared with 19% in the prior-year quarter, primarily due to new royalties tied to the Novitium license agreement. Research and development expenses declined 7.1% to $46.6 million, reflecting the absence of a $15-million CiRC upfront payment recorded a year ago. Sales and marketing expenses increased 13.5% to $34.1 million due to the expansion of field-based teams. General and administrative expenses decreased 17.3% to $28.1 million due to a charge related to an ANDA settlement in the second quarter of 2025. Cash, cash equivalents and investments totaled $962.5 million as of June 30, 2026, up from $882.5 million as of 2025-end. Harmony Pipeline Updates Highlight BP-205 In April 2024, the company expanded into orexin-based therapies through a sublicense agreement with Bioprojet for BP-205, an investigational orexin-2 receptor agonist being developed for narcolepsy and other central nervous system (CNS) disorders. The agreement grants exclusive rights to develop, manufacture and commercialize BP-205 in the United States and Latin America. Harmony reported favorable phase I single-ascending-dose data for BP-205, its orexin-2 receptor agonist. The candidate demonstrated a short time to maximum plasma concentration (30-75 minutes) and a mean half-life of approximately 25 hours, supporting the potential for rapid onset and once-daily dosing. Exposure increased proportionally across the tested doses. BP-205 was generally safe and well tolerated, with no serious or severe treatment-emergent adverse events. Multiple-ascending-dose data in healthy volunteers are expected in the fourth quarter of 2026. Harmony also plans to begin a phase Ib study in sleep-deprived healthy volunteers during the third quarter, with data expected in early 2027. Phase II studies across multiple central nervous system indications are scheduled to begin in mid-2027. HRMY Advances Pitolisant and Epilepsy Assets The FDA accepted the new drug application for pitolisant GR, assigning a target action date of April 1, 2027. The gastro-resistant formulation is designed to reduce gastrointestinal side effects and allow patients to begin treatment at a therapeutic dose without titration. Harmony is pursuing label expansion opportunities for pitolisant beyond narcolepsy, targeting rare neurological disorders such as Prader-Willi syndrome (PWS) and myotonic dystrophy type 1 (DM1). Phase III ONSTRIDE studies of high-dose pitolisant in narcolepsy and idiopathic hypersomnia remain underway, with top-line data expected in 2027. Top-line results are expected in mid-2027. The company is conducting the phase III TEMPO study in PWS, supported by FDA alignment, which has the potential to serve as the registrational trial and support the company’s efforts to seek pediatric exclusivity for pitolisant. The FDA granted Orphan Drug designation to pitolisant for the treatment of PWS in 2024. The company also strengthened its rare epilepsy pipeline by acquiring Epygenix Therapeutics, gaining exclusive rights to develop EPX-100 (clemizole hydrochloride) for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).EPX-100 is being evaluated in the phase III LIGHTHOUSE study for LGS and the ARGUS study for DS. Top-line results from both rare-epilepsy programs are expected in the first half of 2027, with potential regulatory action targeted for 2028. Harmony Reiterates 2026 Revenue Outlook Harmony reaffirmed its 2026 Wakix net revenue guidance of $1 billion to $1.04 billion. Wakix net product revenues rose 21% sequentially in the second quarter, reflecting a rebound from the seasonal market-access headwinds that affected patient starts during the first quarter. Management expects patient growth to continue steadily through the second half of the year, supported by the expanded commercial infrastructure. The average patient increase was the second highest in the product’s seven-year commercial history. Four of the past five quarters generated more than 400 patient additions, indicating steady demand within the narcolepsy market. Management attributed the strong performance to Wakix’s position as the only non-scheduled treatment option for narcolepsy. The product has payer coverage for more than 80% of covered lives and is used both as a standalone therapy and in combination with other narcolepsy therapies. It turns out, estimates revision have trended upward during the past month. At this time, Harmony Biosciences has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. However, the stock has a grade of A on the value side, putting it in the top 20% for value investors. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Harmony Biosciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Harmony Biosciences belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Myriad Genetics (MYGN), has gained 2.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Myriad reported revenues of $190.7 million in the last reported quarter, representing a year-over-year change of -10.5%. EPS of -$0.25 for the same period compares with $0.05 a year ago. For the current quarter, Myriad is expected to post a loss of $0.16 per share, indicating a change of 0% from the year-ago quarter. The Zacks Consensus Estimate has changed -118.2% over the last 30 days. Myriad has a Zacks Rank #5 (Strong Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Myriad Genetics, Inc.? Here are five stocks we like better. Myriad Genetics’ second-quarter revenue fell 11% to $190.7 million, pressured by lower test volumes, reduced reimbursement and a 9% decline in revenue per test. The company reported a $16.9 million adjusted EBITDA loss and a $0.25 adjusted loss per share. The company cut 2026 revenue guidance to $770 million–$790 million and gross-margin guidance to 66%–67%, while suspending adjusted EBITDA guidance. Management cited prenatal weakness, hereditary-cancer reimbursement pressure and uncertainty around its efficiency initiatives. Myriad launched reimbursement and organizational-efficiency programs, including AI-enabled revenue-cycle tools and the Ascend initiative. Product development continued with Prolaris + AI, expanded Precise MRD availability and the FirstGene prenatal screening launch, while Cancer Care and mental-health test volumes increased. Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on results. The company lowered its full-year revenue and gross-margin outlook and suspended adjusted EBITDA guidance amid reimbursement pressure and uncertainty surrounding a broad organizational efficiency initiative. Chief Executive Officer Sam Raha said the quarter included solid demand in the company’s Cancer Care Continuum and mental health portfolios, where test volumes rose 6% and 4%, respectively. Those gains were offset by a 9% decline in prenatal testing volume. → Why SK hynix Could Be the Best AI Chip Stock to Buy Now Exact Sciences Serves Investors Exactly What They Wished For Average revenue per test was affected by approximately $11 million of lower-than-expected prior-period collections, including a $4 million write-off of aged receivables. Excluding that impact, average revenue per test declined 3% year over year, according to the company. Myriad lowered its 2026 revenue guidance to $770 million to $790 million and projected gross margin of 66% to 67%. At the midpoint, the revenue outlook represents a $90 million reduction from its previous forecast, Chief Financial Officer Ben Wheeler said. → Microsoft Just Flipped the AI Spending Narrative Overnight The company cited weaker-than-expected prenatal volume, lower reimbursement levels in hereditary cancer testing, and final resolution of GeneSight accounts receivable as primary reasons for the revision. Management expects third-quarter revenue to be flat to slightly above the second quarter, followed by improvement in the fourth quarter. Myriad suspended its adjusted EBITDA guidance because the timing and financial effects of its initiatives remain uncertain. The company posted an adjusted EBITDA loss of $16.9 million in the second quarter and an adjusted loss per share of $0.25. → Carrier Earnings Could Send the Stock to a New All-Time High Gross margin was 66.6%, down about 460 basis points year over year. Excluding the $11 million impact from revenue changes in estimate, gross margin would have been 68.4%, Wheeler said. The company ended the quarter with approximately $190 million in available liquidity. Raha said payer-related revenue-cycle friction became more aggressive during the quarter, particularly for the MyRisk hereditary cancer panel. The pressure included changing prior-authorization requirements, increased medical-record requests and higher denial rates from a limited number of payers. He said the changes did not reflect shifts in medical policy or the clinical value of the tests. Management said its revised outlook assumes no recovery in average revenue per test from second-quarter levels. Wheeler said reimbursement friction is expected to remain a headwind through the remainder of 2026, although the company does not expect the magnitude of the second-quarter impact to recur. Myriad is implementing revenue-cycle changes intended to improve collections and reduce administrative burdens. These efforts include enhanced coverage verification and prior-authorization workflows, integration with third-party medical-record repositories, and AI-enabled processes for document classification, denial triage, appeals and payer-response management. The company also launched a payer-by-payer market-access initiative for MyRisk, focused on policy engagement, laboratory-benefit-manager collaboration and reimbursement optimization. Separately, Myriad has begun an initiative called Ascend, supported by a professional services firm, to assess the company’s organizational structure, operating model and core processes. Raha said the initiative is designed to improve efficiency, productivity and scalability, with meaningful profitability benefits expected in 2027 and beyond. Management is also conducting a portfolio review to determine the optimal allocation of capital and evaluate actions that could improve shareholder value. The company did not provide a timetable for either the Ascend initiative or the portfolio review. The Cancer Care Continuum business generated second-quarter revenue of $114.1 million, down 11% year over year. Test volume increased 6%, but average revenue per test declined 15%. Hereditary cancer testing volume increased 8%, while MyRisk volume grew 10%. Brian Donnelly, Myriad’s chief commercial officer, said testing among unaffected patients delivered its strongest quarterly performance in three years. During the quarter, Myriad launched Prolaris + AI, an AI-enhanced prostate cancer test combining molecular, AI, biomarker, germline and genomic insights. Donnelly said early feedback from urologists has been positive, particularly for use in active-surveillance decisions. The company also expanded availability of its Precise MRD test for patients with breast, colorectal and renal cancers and submitted its breast-cancer indication to MolDX for a coverage determination. Myriad said it remains on track for a full commercial launch of Precise MRD in 2027. Donnelly said the company has seen a growing number of clinicians and sites use Precise MRD, including repeat orders from some providers. Myriad is continuing to improve digital ordering capabilities and customer workflows based on feedback from early users. Myriad also said it hired, trained and deployed more than 100 new account executives, primarily for the Cancer Care Continuum portfolio. The company expects those hires to begin contributing more meaningfully to volume growth in 2027 and beyond. Prenatal health revenue was $40 million, down 16% year over year, reflecting a 9% volume decline and an 8% decrease in revenue per test. Donnelly attributed the performance to factors including the timing of the sales-force expansion and competitive dynamics. The company’s dedicated prenatal sales team is now fully staffed. Myriad commercially launched FirstGene during the quarter, offering simultaneous screening of carrier status, fetal single-gene conditions, fetal chromosome status and fetal RHD status in one report. Management said early customer feedback has highlighted the product’s single-gene and RHD components as well as its turnaround-time characteristics. GeneSight, Myriad’s mental health test, generated $36.8 million in revenue, down 3% year over year despite 4% volume growth. The business was affected by the aged-receivables write-off, although management said reimbursement trends in mental health have improved with increased payer coverage and biomarker legislation. GeneSight reached more than 40,000 ordering clinicians during the quarter, a record high for the business. Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual's risk for various hereditary conditions and to guide personalized treatment decisions. The company's core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women's health, neurology and pharmacogenomics to support more informed clinical decision-making. Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Myriad Genetics Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

This article first appeared on GuruFocus. Total Revenue: $190.7 million, down 11% year over year. Test Volume: Decreased 1% year over year. Average Revenue per Test: Decreased 9% year over year, including an $11 million headwind from lower prior period collections. Cancer Care Continuum Revenue: $114.1 million, down 11% year over year, with test volume growth of 6% offset by a 15% decline in average revenue per test. Hereditary Cancer Testing Volume: Grew 8% year over year, with MyRisk test volume growth of 10%. Prenatal Health Revenue: $40 million, down 16% year over year, reflecting an 8% decline in average revenue per test and a 9% volume decline. Mental Health Revenue (GeneSight): $36.8 million, down 3% year over year on 4% volume growth, impacted by a $4 million write-off of aged receivables. Gross Margin: 66.6%, down approximately 460 basis points year over year; excluding the $11 million impact from changes in estimate, gross margin was 68.4%. Adjusted Operating Expenses: Increased by $6.7 million year over year. Adjusted EPS: Loss of $0.25 for the quarter. Adjusted EBITDA: Loss of $16.9 million. Liquidity: Approximately $190 million in available capital. Full-Year 2026 Revenue Guidance: Lowered to $770 million to $790 million. Full-Year 2026 Gross Margin Guidance: Lowered to 66% to 67%. Warning! GuruFocus has detected 5 Warning Signs with MYGN. Is MYGN fairly valued? Test your thesis with our free DCF calculator. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Myriad Genetics Inc (NASDAQ:MYGN) reported solid test volume growth in its cancer care continuum and mental health portfolios, with 6% and 4% year-over-year increases, respectively. Hereditary cancer testing volume grew 8% year-over-year, with MyRisk volume up 10%, driven by strong demand in the unaffected population, which saw its highest quarterly volume in three years. The company achieved key pipeline milestones, including the launch of Prolaris Plus AI, expansion of Precise MRD to colorectal and renal cancers, and submission of Precise MRD for breast cancer to MolDx for coverage determination. Myriad Genetics Inc (NASDAQ:MYGN) successfully hired, trained, and placed over 100 new account executives to support cancer care continuum offerings, expected to drive volume growth in 2027 and beyond. The company launched FirstGene, a differentiated prenatal test offering simultaneous screening for carrier status, fetal single gene, chromosome, and RHD status, with positive early feedback and a competitive turnaround time. Mental health testing (GeneSight) saw record-high ordering provider base exceeding 40,000 clinicians, with improving reimbursement trends aided by biomarker legislation. The company maintains a strong liquidity position with approximately $190 million in available capital, providing financial flexibility to execute strategic priorities. Myriad Genetics Inc (NASDAQ:MYGN) is advancing initiatives like the Ascend organizational efficiency program and a rigorous portfolio review, which are expected to materially improve profitability in 2027 and beyond. Myriad Genetics Inc (NASDAQ:MYGN) reported a significant 11% year-over-year decline in total revenue for Q2 2026, with a 9% drop in average revenue per test. The company faced elevated payer friction, including higher denial rates and prior authorization requirements, leading to an $11 million headwind from lower prior-period collections and a $4 million write-off of aged receivables. Prenatal health revenue declined 16% year-over-year, with volume down 9%, reflecting competitive dynamics and slower-than-expected progress in this segment. The company lowered its full-year 2026 revenue guidance to $770-$790 million, a $90 million reduction from prior outlook, and suspended its adjusted EBITDA guidance due to uncertainty. Average revenue per test for hereditary cancer testing declined 15% year-over-year in the cancer care continuum, with continued reimbursement pressure expected through the second half of 2026. The company reported an adjusted EPS loss of $0.25 for the quarter, reflecting softer revenue and stable operating expenses amid ongoing investments. Myriad Genetics Inc (NASDAQ:MYGN) acknowledged that it should have engaged earlier with payers to mitigate reimbursement issues, indicating a reactive approach to evolving conditions. The revised guidance assumes no improvement in average revenue per test from Q2 levels and no contribution from commercial team expansion or new product launches, reflecting a conservative outlook. Q: What are the key factors behind the lowered 2026 revenue guidance, and what are the assumptions for the second half of the year? A: Ben Wheeler (CFO) explained that the revised guidance to $770-$790 million reflects three primary factors: weaker prenatal volume trends, lower-than-expected hereditary cancer reimbursement levels, and the final resolution of the HCT aged receivables. The guidance assumes second-half revenue will be approximately in line with the first half, with Q3 flat to slightly higher than Q2 and improvement in Q4. It also assumes no contribution from commercial team expansion or recent product launches. Q: Can you provide more detail on the hereditary cancer testing reimbursement pressure and the specific action plan to mitigate it? A: Sam Raha (CEO) detailed that the pressure stems from payer-initiated revenue cycle friction, including changing prior authorization requirements, more medical record requests, and higher denial ratesnot changes in medical policy. The company is taking immediate actions: optimizing the end-to-end revenue cycle process, enhancing front-end coverage verification, integrating third-party medical record repositories, deploying AI-enabled workflows, and engaging in a policy-based approach with payers. The company believes many payer practices create unnecessary administrative burden and is pursuing industry organizations and policymakers to address these issues. Q: What is the "Ascend" initiative, and what impact is it expected to have on the company's profitability? A: Sam Raha (CEO) announced the activation of "Ascend," an initiative supported by a leading professional services firm to increase organizational efficiency, productivity, and scalability. The initiative is expected to produce meaningful, measurable benefits to profitability, including adjusted EBITDA, in 2027 and beyond. Due to uncertainty regarding the timing and impact of this initiative, the company has suspended its 2026 adjusted EBITDA guidance. Q: How is the company's portfolio review progressing, and what is the expected outcome? A: Ben Wheeler (CFO) stated that the company is conducting a rigorous portfolio review to ensure capital is deployed to the highest value opportunities and to maximize long-term shareholder value. This review, combined with the Ascend initiative and reimbursement performance improvements, is intended to simplify the business, improve execution, and enhance scalability. The company is confident these initiatives can have a material positive impact in 2027 and beyond, though no timeline has been provided. Q: What are the latest developments with the new product launches, particularly Prolaris Plus AI and Precise MRD? A: Brian Donnelly (CCO) reported that Prolaris Plus AI, launched at the end of Q2, has received positive early customer feedback, particularly for supporting decisions in the active surveillance segment. For Precise MRD, the company has moved into expanded availability for breast, colorectal, and renal cancers. Early access sites are providing actionable feedback, with growing clinician adoption and repeat orders. The MRD assay has performed well operationally, and the company remains on track for a full commercial launch in 2027, with a MolDx submission completed for the breast indication. Q: Can you elaborate on the performance of the prenatal health business and the launch of FirstGene? A: Brian Donnelly (CCO) noted that prenatal health revenue declined 16% year-over-year, reflecting a 9% volume decline and an 8% decline in average revenue per test. The company has not made as much progress as expected due to Salesforce expansion timing and competitive dynamics. However, the new dedicated prenatal sales team is now fully staffed. FirstGene, which offers a simultaneous screen of carrier status, fetal single gene, fetal chromosome, and fetal RHD status, launched commercially last week. Early feedback has been positive, particularly regarding the combination of single gene and RHD components and the industry-leading 14-day turnaround time. Q: What are the trends in the mental health (GeneSight) business, and how is the company addressing reimbursement? A: Brian Donnelly (CCO) reported that GeneSight revenue declined 3% year-over-year to $36.8 million, impacted by a $4 million AR write-off, which obscured improving reimbursement trends. Volume grew 4%, and the ordering provider base reached a record high of over 40,000 clinicians. The company is implementing new procedures, such as collecting credit card information at the time of billing, which may offset slight volume growth with improved revenue collection. Sam Raha (CEO) added that the company remains optimistic about the long-term opportunity, supported by biomarker legislation and high NPS scores. Q: How is the company's commercial team expansion progressing, and what impact is expected? A: Brian Donnelly (CCO) confirmed that the company has hired, trained, and placed over 100 new account executives in the field, primarily supporting cancer care continuum products. These new sales team members are expected to begin driving increased volume meaningfully in 2027 and beyond. The company is also seeing healthy cross-selling opportunities, with oncology sales teams promoting both MyRisk and Precise MRD to community-based oncologists and urologists. Q: What is the company's outlook on average revenue per test (ARPT) trends for the remainder of 2026? A: Ben Wheeler (CFO) stated that the company expects reimbursement friction to remain a headwind through the balance of 2026, and this has been incorporated into the revised revenue guidance. However, the company does not expect the magnitude of the Q2 impact to repeat. The updated guidance assumes no improvement in average revenue per test from Q2 levels. Sam Raha (CEO) added that even under scenarios with additional ARPT pressure, HCT remains a highly profitable business with attractive margins and strong cash generation. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance. Maintained strong laboratory operating performance while driving productivity and cost-per-test improvements designed to support industry-leading gross margins. Momentum continues for the Cancer Care Continuum business with second quarter test volume growth of 6% year-over-year, the launch of Prolaris + AI for prostate cancer, the expansion of Precise MRD to include colorectal and renal cancers, and the submission of Precise MRD for breast cancer to MolDX for coverage determination. Engaged leading professional services firm to support initiatives intended to increase efficiency and scalability to accelerate profitable growth. Revised 2026 financial guidance to reflect second quarter results and updated assumptions for business trends in the second half of 2026. SALT LAKE CITY, July 30, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2026, new initiatives focused on driving increased efficiency, productivity and scalability, and revised financial guidance for the full-year 2026. “In the second quarter, we continued to make meaningful progress on the Cancer Care Continuum on a number of fronts, including 6% year-over-year volume growth supported by the ramp up of our expanded sales team, the launch of Prolaris + AI, the expansion of Precise MRD to include colorectal cancer (CRC) and renal cancers, along with the submission of Precise MRD breast to MolDX,” said Sam Raha, President and CEO, Myriad Genetics. “During the quarter, we advanced work on a strategic review with the intention to identify initiatives to increase growth, profitability, and liquidity. We have activated an initiative called Ascend to increase organizational efficiency, effectivity and scalability and are being supported by a leading professional services firm. We are also doing a rigorous evaluation of our product portfolio to determine the optimal allocation of capital and enhancement of shareholder value.” “Myriad Genetics' second quarter 2026 performance fell short of our expectations, as solid demand for our Hereditary Cancer and Mental Health tests was offset by volume challenges in Prenatal Health and increased payer friction. Mitigating average revenue per test pressure for hereditary cancer testing from this increased payer friction is a top priority, and we are executing a comprehensive action plan. The combination of these developments and the first full quarter of increased costs associated with our expanded commercial team yielded pressure on our bottom line in the quarter. While we are revising our full-year 2026 financial guidance due to lower Prenatal Health test volumes and more conservative assumptions regarding average revenue per test, we remain optimistic about our 2027 financial profile as we execute on multiple initiatives." Financial and Operational Highlights Test volumes of 379,000 in the second quarter of 2026 were relatively stable year-over-year. Second quarter of 2026 average revenue per test decreased 9% year-over-year, in part reflecting an $11.0 million reduction to revenue resulting from changes in estimates of cash collections for tests for which the performance obligation had been satisfied in prior periods. The following table summarizes year-over-year testing volume changes in the company's core product categories: The following table summarizes year-over-year revenue changes in the company's core product categories: Product Categories: Cancer Care Continuum – MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris + AI, Precise Tumor, Precise MRD         Prenatal Health – Foresight, Prequel, FirstGene, SneakPeekMental Health – GeneSight Second quarter 2026 gross margin was 66.6%, down 460 basis points from the second quarter 2025. Operating expenses in the second quarter of 2026 were $165.9 million compared to $481.0 million in the second quarter of 2025. The 2025 period included non-cash impairment charges of $316.7 million due primarily to a decline in Myriad Genetics' market capitalization during the first six months of 2025. Adjusted operating expenses in the second quarter of 2026 increased $6.7 million year-over-year to $150.5 million, reflecting the company's multi-year investment in key strategic areas. Operating loss in the second quarter of 2026 was $38.9 million. Cash Flow and Liquidity Second quarter 2026 cash flow used in operations was $8.3 million and adjusted operating cash outflow in the second quarter of 2026 was $7.7 million. Capital expenditures and capitalization of internal-use software costs totaled $3.2 million in the second quarter 2026 resulting in adjusted free cash flow of $(10.9) million in the second quarter of 2026. As of the end of the second quarter of 2026, the company had cash and cash equivalents of $115.2 million. Business Performance and Highlights Cancer Care Continuum The Cancer Care Continuum business delivered revenue of $114.1 million in the second quarter of 2026. Second quarter 2026 hereditary cancer testing revenue decreased 13% year-over-year due to decreases in reimbursement and unfavorable changes in estimates associated primarily with orders from the first quarter of 2026, partially offset by an 8% year-over-year increase in volume. Myriad Genetics launched Prolaris + AI, its first AI-enabled prostate cancer test, in partnership with PATHOMIQ. Myriad Genetics expanded availability of Precise MRD, broadening availability to patients undergoing treatment and surveillance for breast, colorectal and renal cancers. Results from the prospective, 949 sample, multi-center MONITOR-Breast study were published in Future Oncology, which the company believes further supports the clinical validity of Precise MRD in breast cancer. The study, which covered patients with Stage I–III breast cancer across all molecular subtypes, reported that ultrasensitive ctDNA monitoring during neoadjuvant therapy provided real-time insight into treatment response and helped identify patients at increased risk for residual disease. The company shared data at the American Society of Clinical Oncology (ASCO) Annual Meeting underscoring Myriad Genetics' commitment to the Cancer Care Continuum and highlighting its progress in precision oncology. Multiple presentations showcased the prognostic power of Myriad Genetics' ultrasensitive MRD assay, including several presentations that reported interim outcomes from the MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino, National Cancer Center Hospital East, Japan. Other presentations focused on ovarian cancer, gastric cancer, head and neck cancer, and sarcoma also demonstrated the emerging clinical utility of ctDNA as a biomarker of recurrence and therapy response. The company believes this data reinforces the scientific strength behind the company's precision oncology programs and focus on advancing clinically meaningful innovations for patients and providers. In July 2026, Myriad Genetics submitted a request to the Molecular Diagnostics Program (MolDX), administered by Palmetto GBA, a Medicare Administrative Contractor (MAC) for the Centers for Medicare & Medicaid Services (CMS), for a Local Coverage Determination (LCD) to establish Medicare coverage of its Precise MRD test for breast cancer patients. In July 2026, Myriad Genetics announced newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, involving 14 studies and more than 8,000 patients, which the company believes shows that the Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for patients with localized prostate cancer. Prenatal Health The Prenatal Health business delivered revenue of $39.8 million in the second quarter of 2026. Prenatal testing revenue in the second quarter of 2026 declined 16% year-over-year, as volume decreased 9% year-over-year. The multi-site CONNECTOR study, using the company's FirstGene Multiple Prenatal Screen, continues to see progress in enrollment and the company expects this study, if successful, to support future commercial launch activities and expand capabilities in prenatal testing. In July 2026, Myriad Genetics launched the FirstGene Multiple Prenatal Screen, which includes four prenatal genetic screens from a single draw of blood as early as eight weeks gestation. With this launch, Myriad Genetics offers a comprehensive prenatal screening portfolio helping clinicians deliver the right product to the right patient at the right time. Mental Health GeneSight test revenue was $36.8 million in the second quarter of 2026. Second quarter 2026 revenue decreased 3% year-over-year reflecting 4% year-over-year GeneSight volume growth offset by a 6% year-over-year decline in average revenue per test, which reflects a write-off of aged receivables in the quarter. Financial Guidance Myriad Genetics does not provide forward-looking guidance in accordance with accounting principles generally accepted in the United States (GAAP) for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, strategic realignment, costs related to amortization of intangibles from acquisitions, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially. Below is a table summarizing Myriad Genetics' full-year 2026 financial guidance*: As a result of second quarter 2026 performance and strategic initiatives that are underway, Myriad Genetics is suspending its previous full-year 2026 Adjusted EBITDA guidance and is providing full-year 2026 financial guidance only with respect to Revenue and Adjusted Gross Margin % as set forth above. These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. Conference Call and Webcast A conference call will be held today, Thursday, July 30, 2026, at 4:30 p.m. ET to discuss Myriad Genetics’ financial results and business developments for the second quarter of 2026. A live webcast of the conference call can be accessed on Myriad Genetics' Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register at https://register-conf.media-server.com/register/BI4292daa610ad49c2bd69187625a3818d. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at investor.myriad.com. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com. Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, MyChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Foresight Universal Plus, Precise Tumor, Precise Oncology Solutions, Precise Liquid, Precise MRD, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, SneakPeek Snap, Urosuite, myGeneHistory, Health.Illuminated., RiskScore, Prolaris, Prolaris + AI, and GeneSight are registered trademarks or trademarks of Myriad Genetics, Inc. All third-party marks—® and ™—are the property of their respective owners. © 2026 Myriad Genetics, Inc. All rights reserved. Safe Harbor StatementThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to (i) the company's full-year 2026 financial guidance, (ii) the company's strategic initiatives, including organizational design and process improvements, and the expected impact of those initiatives on efficiency, profitability, predictability, and growth, (iii) the company's expectations regarding its 2027 financial profile, and (iv) the company's expectations regarding the CONNECTOR study and future commercial launch activities. These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: the risk that sales and profit margins of the company’s existing tests may decline; the risk that the company may not be able to operate its business on a profitable basis; risks related to the company’s ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to recent changes in the company's senior management team and the successful implementation of the company's strategic plan; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the company’s tests or the company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests; the risk that the company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if at all; the risk that the company may not successfully develop new markets or channels for its tests; the risk that licenses to the technology underlying the company’s tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the company’s laboratory testing facilities; risks related to public concern over genetic testing in general or the company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the company’s ability to obtain new corporate partnerships and collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops; risks related to the company’s projections or estimates about the potential market opportunity for the company’s current and future products; the risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company’s tests; the risk of patent-infringement claims or challenges to the validity of the company’s patents; risks related to changes in intellectual property laws covering the company’s tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks and other cybersecurity incidents; risks of new, changing and competitive technologies in the United States and internationally and that the company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products; the risk that the company may be unable to comply with financial or operating covenants under the company’s credit or lending agreements; the risk that the company may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of the company's insurance coverage limits and scope of insurance coverage with respect thereto; and other factors discussed under the heading “Risk Factors” contained in Part I, Item 1A of the company’s Annual Report on Form 10-K filed with the SEC on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. The company is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Investor ContactMatt Scalo(801) [email protected] Media ContactAndria Rosell(385) [email protected] Statement Regarding Use of Non-GAAP Financial Measures In this press release, the company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company’s business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of each schedule. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, if available, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company does not forecast GAAP gross margin because it cannot predict certain elements that are included in reported GAAP results. Please see above under “Financial Guidance” for a full explanation. Reconciliation of GAAP to Non-GAAP Financial Measuresfor the Three and Six Months Ended June 30, 2026 and 2025(unaudited data in millions, except per share amounts)

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates. Is now the time to buy Myriad Genetics? Find out in our full research report. Revenue: $190.7 million vs analyst estimates of $207.8 million (10.5% year-on-year decline, 8.2% miss) Adjusted EPS: -$0.25 vs analyst estimates of -$0.06 (significant miss) Adjusted EBITDA: -$16.9 million vs analyst estimates of $218,040 (-8.9% margin, significant miss) The company dropped its revenue guidance for the full year to $780 million at the midpoint from $870 million, a 10.3% decrease Operating Margin: -20.4%, up from -154% in the same quarter last year Free Cash Flow was -$11.5 million compared to -$16.4 million in the same quarter last year Market Capitalization: $476 million “In the second quarter, we continued to make meaningful progress on the Cancer Care Continuum on a number of fronts, including 6% year-over-year volume growth supported by the ramp up of our expanded sales team, the launch of Prolaris + AI, the expansion of Precise MRD to include colorectal cancer (CRC) and renal cancers, along with the submission of Precise MRD breast to MolDX,” said Sam Raha, President and CEO, Myriad Genetics. Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. A company’s long-term sales performance is one signal of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Regrettably, Myriad Genetics’s sales grew at a mediocre 4% compounded annual growth rate over the last five years. This fell short of our benchmark for the healthcare sector and is a poor baseline for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Myriad Genetics’s recent performance shows its demand has slowed as its revenue was flat over the last two years. This quarter, Myriad Genetics missed Wall Street’s estimates and reported a rather uninspiring 10.5% year-on-year revenue decline, generating $190.7 million of revenue. Looking ahead, sell-side analysts expect revenue to grow 10.9% over the next 12 months, an improvement versus the last two years. This projection is healthy and implies its newer products and services will catalyze better top-line performance. ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention. AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice. Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes. Myriad Genetics’s high expenses have contributed to an average adjusted operating margin of negative 1.7% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle. Looking at the trend in its profitability, Myriad Genetics’s adjusted operating margin decreased by 3.8 percentage points over the last five years. This performance was caused by more recent speed bumps as the company’s margin fell by 5 percentage points on a two-year basis. We’re disappointed in these results because they show its expenses were rising and it couldn’t pass those costs onto its customers. This quarter, Myriad Genetics generated a negative 16.6% adjusted operating margin. The company’s consistent lack of profits raises a flag. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable. Myriad Genetics’s earnings losses deepened over the last five years as its EPS dropped 7.4% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Myriad Genetics’s low margin of safety could leave its stock price susceptible to large downswings. In Q2, Myriad Genetics reported adjusted EPS of negative $0.25, down from $0.05 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street is optimistic. Analysts forecast Myriad Genetics’s full-year EPS will flip from negative $0.30 to positive $0.18. We struggled to find many positives in these results. Its full-year revenue guidance missed and its revenue fell short of Wall Street’s estimates. Overall, this quarter could have been better. The stock traded down 28.6% to $3.84 immediately after reporting. The latest quarter from Myriad Genetics’s wasn’t that good. One earnings report doesn’t define a company’s quality, though, so let’s explore whether the stock is a buy at the current price. We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.

Interested in Quest Diagnostics Incorporated? Here are five stocks we like better. Quest Diagnostics posted strong Q2 results, with revenue up 10.2% to $3.04 billion and adjusted EPS rising to $3.12, helped by broad demand across physician, hospital and consumer channels plus contributions from Corewell Health and Fresenius Medical Care. The company raised its full-year 2026 outlook, now expecting revenue of $11.95 billion to $12.05 billion and adjusted EPS of $11.05 to $11.25, while still forecasting operating margin expansion despite higher second-half spending and fuel costs. Growth was broad-based across key businesses, including double-digit gains in hospital testing and advanced diagnostics, strong momentum in consumer health, and continued automation and AI initiatives aimed at improving efficiency and costs. Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medical Care. On the company’s second-quarter earnings call, Chairman, Chief Executive Officer and President Jim Davis said Quest grew revenue by more than 10% in the quarter, driven by “broad clinical demand from physicians, hospitals, and consumers” and higher volume tied to the Corewell and Fresenius relationships. Chief Financial Officer Sam Samad said consolidated revenue was $3.04 billion, up 10.2% from the prior year, while consolidated organic revenue rose 10%. → Could Truth API Become Trump Media’s First Meaningful Revenue Driver? LifeMD Shares Come Back to Life on GLP-1 Business Growth Total volume, measured by requisitions, increased 13.1% compared with the second quarter of 2025, including 13% organic volume growth. Samad said the Corewell Health and Fresenius Medical Care relationships contributed 9% to volume in the quarter. Excluding those two relationships, volumes rose 4.1%. Reported operating income was $459 million, or 15.1% of revenue, compared with $438 million, or 15.9% of revenue, a year earlier. Adjusted operating income was $502 million, or 16.5% of revenue, compared with $466 million, or 16.9% of revenue, last year. Samad said the increase in adjusted operating income reflected organic revenue growth, partially offset by wage increases. → 3 Photonics Companies Making Quantum Tech Possible Exact Sciences Serves Investors Exactly What They Wished For Reported diluted earnings per share were $2.84, compared with $2.47 a year earlier. Adjusted diluted EPS was $3.12, up from $2.62 in the prior-year period. Samad said the EPS improvement was driven by organic operating performance and the favorable resolution of various tax contingencies, which contributed $0.10 per share in the quarter. Excluding that one-time tax benefit, adjusted EPS grew 15.3%. Quest raised its full-year 2026 revenue and earnings outlook, citing first-half performance and ongoing demand. The company now expects: Revenue of $11.95 billion to $12.05 billion, representing growth of 8.3% to 9.2%. Reported EPS of $9.97 to $10.17. Adjusted EPS of $11.05 to $11.25. Cash from operations of approximately $1.8 billion. Capital expenditures of approximately $550 million. → AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off Samad said the guidance excludes any contribution from prospective mergers and acquisitions. He also noted that Project Nova expenses are unchanged for the full year, but the company now expects increased spending in the second half compared with prior expectations. Higher fuel costs in the second half are also included in the outlook. Despite those pressures, Samad said Quest still expects operating margin to expand versus the prior year. He said the company expects to lap the Corewell and Fresenius impacts in the fourth quarter, reducing their dilutive effect on total operating margins in the second half. Davis said the physician channel delivered high single-digit revenue growth during the quarter, supported by demand for clinical innovations, new customer wins and expanded business with existing customers. He cited growth in geographies where Quest has expanded access through health plans and acquisitions, as well as enterprise accounts focused on prevention and wellness. In hospitals, Davis said revenue grew at a double-digit rate, primarily from co-lab solutions with Corewell Health in Michigan. Reference testing revenue also increased versus both the first quarter and the prior year. During the question-and-answer portion of the call, Davis said the company’s core hospital reference business generated mid-single-digit revenue growth, with slightly higher volume growth. He said same-store sales in co-lab arrangements excluding Corewell also grew at a mid-single-digit rate. Davis said Quest formed a new co-lab agreement during the quarter with a nonprofit regional health system in California. He added that the company has a “strong pipeline” of potential hospital collaborations, hospital outreach acquisitions and independent lab opportunities. In consumer health, Davis said questhealth.com continued to generate “robust revenue growth,” with strong demand for existing wellness panels and new services including thyroid testing. He said the broader consumer business, which includes direct and indirect offerings, was previously sized at about $250 million and is currently growing toward the high end of the company’s 20% to 30% expectation for 2027. Davis said Quest posted double-digit revenue growth across several advanced diagnostic areas, including cardiometabolic testing such as ApoB and Lp(a), liver fibrosis testing and autoimmune testing through the company’s analyzer solution. In brain health, he said the company continued to drive “robust double-digit growth” across its AD-Detect blood tests, including amyloid beta and p-tau biomarkers. In oncology, Davis highlighted New York State approval of the Haystack MRD test, which he said allows Quest to extend commercial efforts to all 50 states. He also said Quest became the largest reference lab to extend access to cancer tests such as Haystack MRD through Flatiron Health’s OncoEMR molecular profiling integration platform. A pilot with American Oncology Network has begun, with plans to roll out to Flatiron’s 4,700 clinicians and other providers nationwide later this year. Davis also discussed operational initiatives, saying Quest remains on track to deliver 3% in annual cost savings and productivity improvements through its Invigorate program. He pointed to expanded use of automation and artificial intelligence, including Hologic’s Genius Digital Diagnostics System for Pap test slide review, front-end specimen processing automation, a web-based collection tool called IntelliDraw and an AI tool intended to reduce the time needed to track and order supplies at patient service centers. Asked about Affordable Care Act exchange-related impacts, Davis said Quest continues to assume a 30-basis-point revenue impact from the expiration of ACA exchange subsidies. He said enrollment declines have not translated into a major business impact, noting that requisition volume in that book is down about 8%, but tests per requisition are up 6%, leaving test volume down about 2% and revenue “relatively flat.” Executives also said they are not seeing deterioration in bad debt trends. Samad said hospital collections remain in line with expectations and that patient concessions, which he said typically hover around 5% of revenue, have not worsened and were slightly improved versus the prior-year quarter. On PAMA, Davis outlined three possible outcomes: new CMS rates following the current data collection process, passage of the RESULTS Act, or another delay. He said Quest supports the RESULTS Act, which he described as a better method for collecting market data through a third-party approach. Davis said the bill has more than 115 co-sponsors and broad support from patient and consumer organizations. If the RESULTS Act passes, he said rates would stay flat for 2027 and 2028, with new rates taking effect in 2029 and annual cuts capped at no more than 5%. Davis closed the call by saying Quest entered the second half with growth momentum and continued demand for lab insights, while remaining focused on its strategy of connecting patients and providers to testing and actionable health information. Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening. Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Quest Diagnostics Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.